Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer

[Image: see text] Despite advances in precision medicine approaches over the past decade, the majority of nonsmall cell lung cancers (NSCLCs) are refractory to treatment with targeted small molecule inhibitors. Previous work has identified mutations in the Discoidin Domain Receptor 2 (DDR2) kinase a...

Descripción completa

Detalles Bibliográficos
Autores principales: Terai, Hideki, Tan, Li, Beauchamp, Ellen M., Hatcher, John M., Liu, Qingsong, Meyerson, Matthew, Gray, Nathanael S., Hammerman, Peter S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2015
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4685943/
https://www.ncbi.nlm.nih.gov/pubmed/26390252
http://dx.doi.org/10.1021/acschembio.5b00655

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4685943/
https://www.ncbi.nlm.nih.gov/pubmed/26390252
http://dx.doi.org/10.1021/acschembio.5b00655

Ejemplares similares